Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Dyadic International, Inc is a biotechnology business based in the US. Dyadic International shares (DYAI) are listed on the NASDAQ and all prices are listed in US Dollars. Dyadic International employs 6 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.77|
|52-week range||$3.15 - $9.19|
|50-day moving average||$3.53|
|200-day moving average||$4.65|
|Wall St. target price||$6.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||6.80%|
|3 months (2021-05-03)||-24.45%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
|Revenue TTM||$1.7 million|
|Gross profit TTM||$176,990|
|Return on assets TTM||-21.37%|
|Return on equity TTM||-34.72%|
|Market capitalisation||$106.6 million|
TTM: trailing 12 months
There are currently 722,963 Dyadic International shares held short by investors – that's known as Dyadic International's "short interest". This figure is 8% down from 785,786 last month.
There are a few different ways that this level of interest in shorting Dyadic International shares can be evaluated.
Dyadic International's "short interest ratio" (SIR) is the quantity of Dyadic International shares currently shorted divided by the average quantity of Dyadic International shares traded daily (recently around 298745.04132231). Dyadic International's SIR currently stands at 2.42. In other words for every 100,000 Dyadic International shares traded daily on the market, roughly 2420 shares are currently held short.
However Dyadic International's short interest can also be evaluated against the total number of Dyadic International shares, or, against the total number of tradable Dyadic International shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Dyadic International's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Dyadic International shares in existence, roughly 30 shares are currently held short) or 0.0773% of the tradable shares (for every 100,000 tradable Dyadic International shares, roughly 77 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Dyadic International.
Find out more about how you can short Dyadic International stock.
We're not expecting Dyadic International to pay a dividend over the next 12 months.
Over the last 12 months, Dyadic International's shares have ranged in value from as little as $3.15 up to $9.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dyadic International's is -0.0201. This would suggest that Dyadic International's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Dyadic International has bucked the trend.
Dyadic International, Inc. , a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd. ; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S. L.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.